本帖最后由 老马 于 2013-3-13 13:43 编辑
" Q4 y' b1 N+ y4 C
1 N+ |# M# `3 W4 X7 s健择（吉西他滨）+顺铂+阿瓦斯汀6 ?5 h- o" R$ A& d ?/ m# F' J
Gemzar +Cisplatin + Avastin
! c$ |* r; n; X' W2 Ahttp://annonc.oxfordjournals.org/content/21/9/1804.full( u3 S9 }: r6 x j" t; Z
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) " W( g7 S3 u5 y' q( S' ^
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. ) [" {* A0 u* d I- X) q# F& f8 }) U
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
, b& G( m! t2 ^: h$ ~
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 244)
5 D5 z0 M1 C$ ~& v
华为网盘附件：1 m/ [7 h: \( K6 v
【华为网盘】ava.JPG# q+ z0 b x0 R. E. r" E
|
显身卡
